ASRS 2023: Efficacy/safety of biosimilars ranibizumab-nuna and ranibizumab-eqrn in clinical use
July 30th 2023This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.
ASRS 2023: Premier meeting for retina science and innovation
July 13th 2023ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.
SOE 2023: New dehydrated human amniotic membrane promotes healing of the ocular surface
June 15th 2023Omnigen® may be an alternative treatment option for patients with a persistent corneal epithelial defect. The product provides a convenient and effective treatment that can be administered in an outpatient setting.